All In Biotech

Drug Trial Radar · NCT04225156

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Jun 2, 2020

Primary completion

Mar 11, 2026

Study completion Mar 11, 2026

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Jan 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

  • efgartigimodBiological

    Intravenous infusion of efgartigimod

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of Adverse EventsTime frame: Up to 60 weeks
  2. Frequency and severity of vital signsTime frame: Up to 60 weeks
  3. Frequency and severity of laboratory assessmentsTime frame: Up to 60 weeks

Locations

87 sites in 18 countries. Site status is shown where the registry gives one.

  • Investigator Site 0010045

    Washington D.C., District of Columbia

  • Investigator Site 0010037

    Ocala, Florida

  • Investigator Site 0010042

    Iowa City, Iowa

  • Investigator Site 0010040

    Columbus, Ohio

  • Investigator Site 0430002

    Vienna, Austria

  • Investigator Site 0430003

    Vienna, Austria

  • Investigator Site 0320012

    Brasschaat, Belgium

  • Investigator Site 0320011

    Bruges, Belgium

  • Investigator Site 0320014

    Turnhout, Belgium

  • Investigator Site 0320002

    Yvoir, Belgium

  • Investigator Site 3590001

    Pleven, Bulgaria

  • Investigator Site 3590002

    Sofia, Bulgaria

  • Investigator Site 4200001

    Brno, Czechia

  • Investigator Site 4200008

    Olomouc, Czechia

  • Investigator Site 4200006

    Ostrava, Czechia

  • Investigator Site 4200007

    Prague, Czechia

  • Investigator Site 0330009

    Créteil, France

  • Investigator Site 0330018

    Montpellier, France

  • Investigator Site 0330016

    Périgueux, France

  • Investigator Site 0330008

    Pessac, France

  • Investigator site 9950007

    Tbilisi, Georgia

  • Investigator site 9950008

    Tbilisi, Georgia

  • Investigator site 9950009

    Tbilisi, Georgia

  • Investigator site 9950011

    Tbilisi, Georgia

  • Investigator site 9950012

    Tbilisi, Georgia

  • Investigator Site 0490010

    Düsseldorf, Germany

  • Investigator Site 0490008

    Essen, Germany

  • Investigator Site 0360004

    Budapest, Hungary

  • Investigator Site 0360006

    Debrecen, Hungary

  • Investigator Site 0360015

    Győr, Hungary

  • Investigator Site 0360010

    Nyíregyháza, Hungary

  • Investigator Site 0360014

    Szombathely, Hungary

  • Investigator Site 0390014

    Milan, Italy

  • Investigator Site 0390020

    Monza, Italy

  • Investigator Site 0390015

    Novara, Italy

  • Investigator Site 0390010

    Ravenna, Italy

  • Investigator Site 0390011

    Reggio Calabria, Italy

  • Investigator Site 0390018

    Reggio Emilia, Italy

  • Investigator Site 0390019

    Rimini, Italy

  • Investigator Site 0390009

    Siena, Italy

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.